In Vitro Cell Proliferation, Osteogenic Differentiation, and In Vivo Angiogenesis Induced by Modified mRNA Encoding Vascular Endothelial Growth Factor-A.
Noppadol Sa-Ard-Iam, Mana Naratippakorn, Chantrakorn Champaiboon
{"title":"In Vitro Cell Proliferation, Osteogenic Differentiation, and In Vivo Angiogenesis Induced by Modified mRNA Encoding Vascular Endothelial Growth Factor-A.","authors":"Noppadol Sa-Ard-Iam, Mana Naratippakorn, Chantrakorn Champaiboon","doi":"10.1155/ijod/8805818","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to determine whether pseudouridine-modified mRNA encoding vascular endothelial growth factor (VEGF) -A induces VEGF production in human periodontal ligament cells (PDLCs), and to evaluate its effects on PDLC proliferation, osteogenic differentiation, and in vivo angiogenesis.</p><p><strong>Methods: </strong>PDLCs derived from healthy periodontal tissues were transfected with pseudouridine-modified VEGF-A mRNA using Lipofectamine 2000 (L2000) or treated with L2000 alone. VEGF secretion was quantified at 24-72 h posttransfection. Cell viability and immune activation were also assessed. Supernatants collected at 48 h were used to evaluate PDLC proliferation using the AlamarBlue assay. Osteogenic differentiation was assessed by Alizarin Red S staining and the expression of <i>alkaline phosphatase gene</i> (<i>ALPL</i>), <i>RUNX2</i>, and <i>osteocalcin</i> (<i>OCN</i>). Angiogenic activity was evaluated using the chorioallantoic membrane (CAM) assay in fertilized White Leghorn chicken eggs (<i>n</i> = 7 per group). On embryonic day 8, filter papers loaded with supernatants from L2000 + mRNA, L2000 groups, Dulbecco's phosphate-buffered saline, or recombinant VEGF (rhVEGF) were placed on the CAM. After a 3-day incubation, newly formed blood vessels were imaged and quantified.</p><p><strong>Results: </strong>PDLCs transfected with pseudouridine-modified VEGF-A mRNA produced significantly higher VEGF levels than the control groups for up to 72 h (<i>p</i> < 0.05), without affecting cell viability or inducing innate immune activation. VEGF-containing supernatants promoted PDLC proliferation. Direct VEGF mRNA transfection enhanced osteogenic differentiation and upregulated expression of osteogenic markers <i>ALPL</i>, <i>RUNX2</i>, and <i>OCN</i>. In the CAM assay, abundant microvascular networks with a characteristic spoked-wheel pattern were observed in both the VEGF mRNA and rhVEGF groups. Furthermore, the VEGF mRNA group showed a significantly greater increase in blood vessel formation than the control groups (<i>p</i> < 0.01).</p><p><strong>Conclusion: </strong>Pseudouridine-modified VEGF-A mRNA effectively induced VEGF production, which subsequently enhanced PDLC proliferation, osteogenesis, and in vivo angiogenesis. These findings support the potential of pseudouridine-modified VEGF-A mRNA as a promising therapeutic approach for periodontal regeneration.</p>","PeriodicalId":13947,"journal":{"name":"International Journal of Dentistry","volume":"2026 ","pages":"8805818"},"PeriodicalIF":2.2000,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662732/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Dentistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ijod/8805818","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: This study aimed to determine whether pseudouridine-modified mRNA encoding vascular endothelial growth factor (VEGF) -A induces VEGF production in human periodontal ligament cells (PDLCs), and to evaluate its effects on PDLC proliferation, osteogenic differentiation, and in vivo angiogenesis.
Methods: PDLCs derived from healthy periodontal tissues were transfected with pseudouridine-modified VEGF-A mRNA using Lipofectamine 2000 (L2000) or treated with L2000 alone. VEGF secretion was quantified at 24-72 h posttransfection. Cell viability and immune activation were also assessed. Supernatants collected at 48 h were used to evaluate PDLC proliferation using the AlamarBlue assay. Osteogenic differentiation was assessed by Alizarin Red S staining and the expression of alkaline phosphatase gene (ALPL), RUNX2, and osteocalcin (OCN). Angiogenic activity was evaluated using the chorioallantoic membrane (CAM) assay in fertilized White Leghorn chicken eggs (n = 7 per group). On embryonic day 8, filter papers loaded with supernatants from L2000 + mRNA, L2000 groups, Dulbecco's phosphate-buffered saline, or recombinant VEGF (rhVEGF) were placed on the CAM. After a 3-day incubation, newly formed blood vessels were imaged and quantified.
Results: PDLCs transfected with pseudouridine-modified VEGF-A mRNA produced significantly higher VEGF levels than the control groups for up to 72 h (p < 0.05), without affecting cell viability or inducing innate immune activation. VEGF-containing supernatants promoted PDLC proliferation. Direct VEGF mRNA transfection enhanced osteogenic differentiation and upregulated expression of osteogenic markers ALPL, RUNX2, and OCN. In the CAM assay, abundant microvascular networks with a characteristic spoked-wheel pattern were observed in both the VEGF mRNA and rhVEGF groups. Furthermore, the VEGF mRNA group showed a significantly greater increase in blood vessel formation than the control groups (p < 0.01).
Conclusion: Pseudouridine-modified VEGF-A mRNA effectively induced VEGF production, which subsequently enhanced PDLC proliferation, osteogenesis, and in vivo angiogenesis. These findings support the potential of pseudouridine-modified VEGF-A mRNA as a promising therapeutic approach for periodontal regeneration.